Fate Therapeutics (NASDAQ: FATE) reported Q1 EPS of ($0.27), $0.05 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $1.7 million versus the consensus estimate of $1.68 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.